SYNTHESIS AND PHARMACOLOGICAL EVALUATION OF CERTAIN SCHIFF BASES OF OCTAHYDRO-1H-PYRROLO [3, 4-B] PYRIDINE DERIVATIVES

SADAGOPAN SEKAR1, NAGARAJA NAIK1, SRIDHARA AJJANNA MAHALINGAPPA2, PEETHAMBER S. K.3

1Department of Studies in Chemistry, University of Mysore, Manasagangotri, Mysore 570006, *Gomti Life sciences India Pvt Ltd, Bidadi Industrial Area, Bangalore 562109, 2Department of Biochemistry, Kuvempu University, Shankaraghatta, Shivamogga, India

Email: drnaikchem@gmail.com

Received: 26 Apr 2015 Revised and Accepted: 25 Jul 2015

INTRODUCTION

Schiff bases are condensation products of primary amines with carbonyl compounds and they were first reported by Schiff in 1864 [1]. The common structural feature of these compounds is the azomethine group with a general formula RHC=N-R1, where R and R1 are alkyls, aryl, cycloalkyl or heterocyclic groups which may be variously substituted. These compounds are also known as anils, imines or azomethines. Several studies showed that the presence of a lone pair of electrons in a sp² hybridized orbital of the nitrogen atom of the azomethine group is of considerable chemical and biological importance. Because of the relative easiness of preparation, synthetic flexibility, and the special property of C=N group, versatility of Schiff base ligands and biological, analytical and industrial applications of their complexes make further investigations in this area highly desirable.

Nowadays, the research field dealing with Schiff base coordination chemistry has expanded enormously. The importance of Schiff base complexes for bioinorganic chemistry, biomedical applications, supramolecular chemistry, catalysis and material science, separation and encapsulation processes, and formation of compounds with unusual properties and structures has been well recognized and well reviewed [2]. Schiff bases shown excellent biological properties like antitumor activity [3], plant growth regulators [4], antimicrobial [5], corrosion inhibitor [6], antiviral [7] anticancerulants [8] antifungal [9] and anthelmintic activities [10], antibacterial activity [11], herbalicidal [12],and in analytical chemistry [13].

Moxifloxacin [14] is a novel antibacterial 8-methoxy fluoroquinolone derivative which exhibits broad-spectrum activity against gram-positive and gram-negative microbes as well as anaerobes. Based on the study and the literature, moxifloxacin is very photostable and does not induce as much photocytotoxicity compared to other analogues of fluoroquinolone drugs [15]. The stability and less photo toxicity is due to the seventh position substitution of the fluoroquinolone ring by an octahydro-1H-pyrrrolo [3,4-b]pyridine moiety and its C-8 position with a methoxy group [16]. It also reported that the substituent effect of different basic moieties dealing with pyridobenzoxazines [17], the order of potency of basic substituents against mycobacteria (from the highest to the lowest) was octahydro-1H-pyrrrolo [3,4-b]pyridine>3-amominomethylpyrroldines>3-aminothiazole>3-aminoazetidine>3-aminoazetidine [18]. Diazabicycloalkanes are important synthetic precursors in the preparation of compounds with a variety of biomedical applications. For example, derivatives of 3,8-diazabicyclo[3.2.1]octane and 1,4-diazabicyclo[3.2.2]nonane were used as the starting materials for the synthesis of various biologically active molecules, including a7 nicotinic acetylcholine receptor agonists, which can be used for the treatment of diseases or disorders related to the central nervous system (CNS) and peripheral nervous system (PNS) [19]. Adducts of 3,8-diazabicyclo[3.2.1]octane, 1,4-diazabicyclo[3.2.2]nonane and other similar diazabicycles with quinolones resulted in products with significant antibacterial activity [20]. 1,4-Diazabicyclo[3.2.2]nonanes also serve as precursors in the preparation of [18F] isotopically containing potential radiotracers for imaging a7 nicotinic acetylcholine receptors [21], whereas 3,10-diazabicyclo[4.3.1]decanes are derivatives in the synthesis of [11C]-labeled serotonin transporter ligands [22]. It is also reported that diazabicyclodecane derivatives used for the treatment and/or prophylaxis of autoimmune disorders and/or inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, cancer, respiratory diseases and fibrosis [23]. Also, it is reported that 8,10-diazabicyclo[4.3.1]decanes are potent nicotinic modulators and may be useful in the treatment of diseases related to the cholinergic system of the CNS or PNS [24]. Pyridine-substituted 3,6-diazabicyclo[3.2.0]heptanes were observed to be selective agonists for α4β2 nicotinic acetylcholine receptor [25]. The azabicycle heterocyclic scaffolds are found in chemokine CCR5 receptor antagonists and inhibitors of dipetidyl peptide IV [26]. The 3,7-Diazabicyclo[4.3.0]nonad-8-ones are shown to be potential nontropic and analgesic drugs [27], antiproteozal [28] and antipsammolytic [29] activities. Following are some of the drugs and drugs analogues which contain diazabicyclononane moiety-Moxifloxacin, BAY3118[30], Pradofloxacin [31], Pyridol[1,2,3-de][1,3,4]benzoxadizine derivatives [32], 6,5-pyrrolopyridine derivatives [33] and tetrahydro-1H-pyrrolo[2,3-c]pyridine derivatives [34].

Abstract

Objective: Synthesis, characterization and biological screening of some new 1,6-disubstituted Octahydro-1H-pyrrrolo [3,4-b]pyridine Schiff base (13a-n) derivatives.

Methods: The scaffold of Octahydro-1H-pyrrrolo [3,4-b]pyridine Schiff bases was prepared, synthesised and screened for their biological activity.

Results: The structure of newly synthesized compounds was characterized by spectral data and screened for their biological activity like antioxidant, antimicrobial, antifungal, and chelating efficacy activities against various bacteria and fungi strains. Screening revealed that several of these compounds (13a-n) showed potential biological activity.

Conclusion: Investigation on newly synthesised 1,6-disubstituted Octahydro-1H-pyrrrolo [3,4-b]pyridine Schiff base (13a-n) derivatives for their biological activity revealed that some of the compounds showed good antioxidant, chelating and antimicrobial properties. The fact that the newly synthesised Schiff bases in this study are chemically related to the current medication and suggests further work is clearly warranted and to be explored.

Keywords: Octahydro-1H-pyrrrolo [3,4-b]pyridine, Schiff base, Moxifloxacin, 8-methoxy fluoroquinolone, DPPH, antioxidants.
The diverse biological activities of octahydropyrrolopyridine or diazabicycles, and Schiff base pharmacophores encouraged us to envisage the molecular modelling, which possesses both these cores in a compact system and to elucidate the potential role of these compounds as active biological agents. In view of interest in the development of simpler and more convenient synthetic routes for achieving the biologically active analogues and in continuation of our research interest in functionalization of new tricyclic and heterocyclic compounds [35-39]. A series of some new 1,6-disubstituted Octahydro-1H-pyrrolo[3,4-b]pyridine Schiff bases (13a-n) were prepared.

Introducing potential bioactive chromophores (Schiff bases) on octahydropyrrolopyridine heterocyclic scaffold (Figure-1) allow us to synthesise various octahydro pyrrolopyridine compounds giving rise to the variety of compounds, which may be screened for diverse biological activity. Substitution at 1 and 6 positions will enable us wide molecular manipulations. In finding out new derivatives of octahydropyrrolopyridine, in this research paper we report a series of new Schiff bases with a potential biological activity resulted from the condensation of aryl aldehydes with 2,2'-hexahydro-1H-pyrrolo[3,4-b] pyridine-1,6(2H)-diyldiacetohydrazide. These compounds may also act as valuable ligands. The structures of newly synthesized Schiff bases were characterized by physic-chemical and spectral data.

Preparation of 6-Benzyl-5H-pyrrolo[3,4-b]pyridine-5,7(6H)-dione (4)

A mixture of benzylamine (3) (57.0 g, 0.532 mol) and quinolinic anhydride (2) (40 g, 0.268 mol) were heated to 100-105 °C for 6 h. After completion of reaction cooled the reaction mass to room temperature, quenched with ice water. Stirred the quenched mass for 30 min, filtered the precipitated product. The crude product was dissolved in ethanol by refluxing and then cooled to crystallize the product and filtered, dried in an air oven at 50-60 °C to constant weight.

Weight: 51 g; Yield: 80 %; Off white solid; mp: 154-156 °C; ESI-MS m/z = 239.1 (M+1); 'H NMR (400 MHz, DMSO-d6) δ 7.72 -7.78 (5H, Ar-H), 7.78 -7.81 (1H, Ar-H), 8.31 -8.33 (1H, dd), 8.99 -9.08 (1H, Ar-H).

Preparation of 6-Benzyltetrahydro-1H-pyrrolo[3,4-b]pyridine-5,7(2H,6H)-dione (5)

6-benzyl-5H-pyrrolo[3,4-b]pyridine-5,7(6H)-dione (50 g, 0.209 mol) in methanol (500 ml) was charged into an autoclave, added 5% Pd/C (5 g) under nitrogen atmosphere into an autoclave. The reaction vessel was evacuated with nitrogen followed by application of hydrogen gas at a pressure of 4.0-4.5 kg/cm². The reaction mixture was heated at a temperature of 55-60 °C for a period of 7 h. After completion of the reaction, cooled to ambient temperature, filtered the catalyst through hyflo supercel bed. The solvent was completely distilled under vacuum at below 45 °C. The residue was crystallized from isopropyl ether to get the desired compound (5).

Weight: 35.0 g; Yield: 68 %; White semi solid; ESI-MS m/z = 245.2 (M+1); 'H NMR (400 MHz, DMSO-d6) δ 1.24 -1.31 (m, 1H), 1.46 -1.57 (m, 1H), 1.75 -1.92 (m, 1H), 2.58 -2.67 (m, 2H), 2.63 -2.67 (m, 1H), 3.15 -3.21 (m, 1H), 4.17 -4.34 (m, 2H), 7.22 -7.23 (m, SH, Ar-H), 7.85 (s, 1H, Ar-H).

Preparation of 6-Benzotetrahydro-1H-pyrrolo[3,4-b]pyridine (6)

Vitrine in toluene (200 g, 0.8735 mol) solution was added to a solution of 6-benzyltetrahydro-1H-pyrrolo[3,4-b]pyridine-5,7(2H,6H)-dione (30 g, 0.1228 mol) in toluene (125 ml) at 0-5 °C. Nitrogen atmosphere was maintained for 30 min and the toluene layer was separated, washed with saturated sodium chloride solution and distilled off the solvent under vacuum at below 60 °C to get the desired product.

Weight: 20.0 g; Yield: 75 %; White solid; ESI-MS: m/z = 217.2 (M+1).

Preparation of Octahydro-1H-pyrrolo[3,4-b]pyridine (7)

A solution of 8-benzyl-2,8-diazabicyclo[4.3.0]nonane (10 g, 0.04622 mol) in methanol (100 ml) is charged into an autoclave, 6% Pd/C (1 g). The reaction mass was heated to 55 °C for 4 hrs under hydrogen pressure, after completion of the reaction, cooled to 25 °C, filtered and washed with methanol (90.0 ml). The solvent was distilled off to get the desired product octahydro-1H-pyrrolo[3,4-b] pyridine.

Weight: 5.0 g; Yield: 86 %; Light yellow colored liquid; ESI-MS m/z = 127.1 (M+1); 'H NMR (400 MHz, DMSO-d6) δ 1.24 -1.31 (m, 1H), 1.35 -1.46 (m, 1H), 1.59 -1.66 (m, 2H), 1.81 -1.89 (m, 1H), 2.21 (brs, 2H), 2.39 -2.45 (m, 1H), 2.50 -2.57 (m, 1H), 2.63 -2.67 (m, 1H), 2.70 -2.82 (m, 1H), 2.95 -2.99 (m, 1H).
Yield 67%; Off white solid; MS (ESI) m/z = 2962, 1682, 1290, 756; δ 8.40 (1H, m, ArH), 11.27 -11.57 (2H, Amide H, N); IR (KBr) ν/cm−1 3447, 2935, 1697, 1246.

[6-(4-Chloro-benzylidine-hydrazinocarbonylmethyl)-octahydro-pyrrolo[3,4-b]pyridin-1-yl]-acetic acid (4-chloro-benzylidine)-hydrazide (13e)

Yield 70%; Off white solid; MS (ESI) m/z= 517.1 (M+1); H NMR (400 MHz, DMSO-d6) δ 1.23 -1.75 (4H, m), 2.25 -2.67 (2H, m), 2.71 -3.00 (6H, m, ArH), 3.03 -3.10 (2H, m), 3.17 -3.28 (2H, m), 7.37 -7.50 (6H, m, ArH), 7.67 -7.71 (4H, m, ArH), 7.96 -8.01 (1H, m, ArH), 8.25 -8.38 (1H, m), 11.33 -11.53 (2H, m); IR (KBr) v/cm−1 3447, 2930, 1692, 1250.

[6-(4-Chloro-benzylidine-hydrazinocarbonylmethyl)-octahydro-pyrrolo[3,4-b]pyridin-1-yl]-acetic acid (4-Chloro-benzylidine)-hydrazide (13f)

Yield 75%; Off white solid; MS (ESI) m/z = 561.1 (M+1); H NMR (400 MHz, DMSO-d6) δ 1.397 -1.554 (4H, m), 1.60 -1.75 (4H, m), 1.72 -1.91 (2H, m), 2.29 -2.46 (2H, m), 2.71 -2.86 (2H, m), 2.90 -3.06 (2H, m), 3.08 -3.10 (2H, m), 3.17 -3.28 (2H, m), 7.37 -7.50 (6H, m, ArH), 7.61 -7.71 (4H, m, ArH), 7.95 -8.00 (1H, m, ArH), 8.25 -8.38 (1H, m), 11.33 -11.53 (2H, m); IR (KBr) v/cm−1 3443, 3233, 3213, 2935, 1690, 1560, 1271.

[6-(4-Chloro-benzylidine-hydrazinocarbonylmethyl)-octahydro-pyrrolo[3,4-b]pyridin-1-yl]-acetic acid (4-Chloro-benzylidine)-hydrazide (13g)

Yield 55%; Off white solid; MS (ESI) m/z = 579.1 (M+1); H NMR (400 MHz, DMSO-d6) δ 1.463 -1.709 (4H, m), 2.26 -2.36 (2H, m), 2.67 -3.07 (6H, m), 3.17 -3.30 (2H, m), 3.41 -3.56 (4H, m), 4.00 -4.14 (1H, m), 6.92 -6.94 (2H, m), 7.21 -7.29 (2H, m), 7.49 -7.56 (4H, m), 7.60 -7.63 (1H, m), 8.20 -8.25 (1H, m), 8.46 -8.58 (1H, m), 11.37 (2H, Brs), 11.62 (2H, Brs); IR (KBr) v/cm−1 3343, 3233, 3213, 2935, 1690, 1560, 1271.

[6-(3,4,5-Tri-methoxy-benzylidine-hydrazinocarbonylmethyl)-octahydro-pyrrolo[3,4-b]pyridin-1-yl]-acetic acid (3,4,5-tri methoxy-benzylidine)-hydrazide (13h)

Yield 52%; Off white solid; MS (ESI) m/z = 627.3 (M+1); H NMR (400 MHz, DMSO-d6) δ 1.23 -1.87 (4H, m), 2.31 -2.33 (2H, m), 2.73 -3.03 (8H, m), 3.14 -3.42 (2H, m), 3.66 -3.99 (1H, m), 7.89 -7.91 (1H, d), 8.21 -8.23 (1H, d), 11.38 (2H, Brs); IR (KBr) v/cm−1 3225, 2940, 1677, 1573, 1235.

[6-(2-Chloro-3-methyl-benzylidine-hydrazinocarbonylmethyl)-octahydro-pyrrolo[3,4-b]pyridin-1-yl]-acetic acid (2-Chloro-3-methyl-benzylidine)-hydrazide (13i)

Yield 45%; Off white solid; MS (ESI) m/z = 517.2 (M), 519.1 (M+2); H NMR (400 MHz, DMSO-d6) δ 1.23 -1.46 (2H, m), 2.19 -2.42 (4H, m), 2.63 -2.86 (4H, m), 2.94 -3.24 (2H, m), 3.29 -3.52 (2H, m), 3.58 -3.91 (2H, m), 7.40 -7.53 (2H, m), 8.21 -8.30 (3H, m), 8.40 -8.43 (1H, m), 11.66 (2H, Brs); IR (KBr) v/cm−1 3341, 3291, 2931, 1694, 1557, 1398.

[6-(4-Hydroxy-3-methoxy-benzylidine-hydrazinocarbonylmethyl)-octahydro-pyrrolo[3,4-b]pyridin-1-yl]-acetic acid (4-Hydroxy-3-methoxy-benzylidine)-hydrazide (13j)

Yield 63%; Off white solid; MS (ESI) m/z = 539.1 (M+1); H NMR (400 MHz, DMSO-d6) δ 1.45 -1.70 (4H, m), 2.29 -2.36 (2H, m), 2.69 -3.00 (7H, m), 3.15 -3.39 (3H, m), 3.69 -3.86 (8H, m), 6.78 -6.85 (2H, m), 6.96 -7.06 (2H, m), 7.19 -7.24 (2H, m), 7.81 -7.85 (1H, m), 8.13 -8.18 (1H, m), 11.18 (2H, brs); IR (KBr) v/cm−1 3070, 2930, 1655, 1546, 1378
(6-N-[2-(1-Methyl-1H-pyrrozol-4-yl)-vinyl]-hydrazinocarboxyl methyl)-octahydro-pyrrolo[3,4-b]pyridin-1-yl)-acetic acid N'-[2-(1-methyl-1H-pyrrozol-4-yl)-vinyl]-hydrazide (13d)

Yield 45%; Off white solid; MS (ESI) m/z 455.3 (M+1); 1H NMR (400 MHz, DMSO-d6) δ 1.46-1.69 (4H, m), 2.27-2.33 (2H, m), 2.67-2.95 (6H, m), 3.00-3.11 (1H, m), 3.32-3.51 (2H, m), 3.71-3.84 (1H, m), 6.99-7.07 (2H, m), 7.36-7.46 (8H, m), 7.48-7.50 (2H, m), 7.94-7.98 (1H, m), 8.26-8.36 (1H, m), 11.48-11.54 (2H, m); 13C NMR (100 MHz, DMSO-d6) δ 22.0, 23.7, 37.69, 48.97, 52.1, 54.91, 57.88, 58.23, 65.53, 129.34, 129.79, 130.69, 141.27, 147.11, 15.07, 167.76, 168.06, 168.39, 172.09, 173.23; IR (KBr) ν/cm⁻¹ 3418, 2931, 1694, 1557, 1378.

(6-N-[2-(1-Methyl-1H-pyrrozol-4-yl)-vinyl]-hydrazinocarboxyl methyl)-octahydro-pyrrolo[3,4-b]pyridin-1-yl)-acetic acid N'-[2-(1-methyl-1H-pyrrozol-4-yl)-vinyl]-hydrazide (13e)

Yield 65%; Off white solid; MS (ESI) m/z 667.3 (M+1); 1H NMR (400 MHz, DMSO-d6) δ 1.36-1.72 (4H, m), 2.18-2.31 (2H, m), 2.61-2.77 (3H, m), 2.82-2.99 (3H, m), 3.03-3.24 (2H, m), 3.29-3.55 (1H, m), 3.71-3.84 (1H, m), 6.99-7.07 (4H, m), 7.37-7.50 (2H, m), 7.94-7.98 (1H, m), 8.26-8.36 (1H, m), 11.48-11.54 (2H, m); 13C NMR (100 MHz, DMSO-d6) δ 22.0, 23.7, 37.6, 48.98, 51.93, 52.34, 55.98, 58.61, 59.16, 117.40, 117.54, 117.82, 118.14, 119.37, 119.88, 119.92, 119.87, 123.95, 124.86, 125.05, 130.59, 132.37, 147.18, 143.47, 145.79, 145.69, 146.17, 153.43, 155.93, 156.79, 156.98, 167.18, 167.60, 167.87, 167.00, 171.97, 173.10; IR (KBr) ν/cm⁻¹ 3225, 2940, 1677, 1573, 1276.

(6-[4-Fluoro-phenoxy]-benzyldene-hydrazinocarboxyl methyl)-octahydro-pyrrolo[3,4-b]pyridin-1-yl)-acetic acid [3-(4-fluoro-phenoxy)-benzyldene]-hydrazide (13f)

Yield 55%; Off white solid; MS (ESI) m/z 619.23 (M+1); 1H NMR (400 MHz, DMSO-d6) δ 1.46-1.69 (4H, m), 2.27-2.33 (2H, m), 2.67-2.95 (6H, m), 3.00-3.11 (1H, m), 3.17-3.28 (1H, m), 3.32-3.50 (1H, m), 3.58-3.81 (1H, m), 3.82-3.90 (6H, m), 7.69-7.70 (2H, m), 7.95-8.05 (2H, m), 8.15 (s, 1H), 8.24 (1H, s), 11.03-11.15 (2H, bs); 13C NMR (100 MHz, DMSO-d6) δ 21.83, 22.97, 37.62, 48.98, 51.93, 52.01, 54.91, 57.88, 58.23, 65.53, 129.34, 129.79, 130.69, 141.27, 147.11, 15.07, 167.76, 168.06, 168.39, 172.09, 173.23; IR (KBr) ν/cm⁻¹ 3418, 2931, 1694, 1557, 1378.

Biological activity
Antioxidant activity

The antioxidant activity of novel Schiff bases (13a-n) were determined by DPPH scavenging activity method as described by Brand-Williams et al. [41] with some modifications. This assay is based on the determination of the concentration of 2, 2-diphenyl-1-picrylhydrazyl (DPPH) in methanolic solution, after adding the antioxidants, DPPH concentration is reduced by the existence of an antioxidant at 515 nm and the absorption gradually disappears with time. UV/VIS spectrophotometer was used to determine the antioxidant activity of each sample. A stock solution (1 mg/ml) of the test compounds was prepared in methanol. 100 μl of the compounds were added to 3 ml of a 0.004% methanol solution of DPPH radical. After 30 min of incubation in the dark at room temperature, the absorbance was observed against a blank at 515 nm. Butylated hydroxy toluene (BHT) was used as reference standard for comparison. All the experiments were carried out triplicate, average and the standard deviations were calculated. The percentage of inhibition was calculated using following formula and reported in Table-1

\[
\% \text{Inhibition} = \frac{A_0 - A_1}{A_0} \times 100
\]

Where A0 is the absorbance of the control reaction and A1 is the absorbance of the sample.

Metal ion chelating assay

The ability of samples to chelate iron (II) ion was estimated using the method reported by Dinis et al. [42] and compared with that of the reference chelator agent EDTA. Test samples of (13a-n) 100 μg concentration (1.0 ml) was added to a solution of 2 ml mol iron(II)chloride (0.05 ml). The reaction was initiated by the addition of 5 ml molferrrozine (0.2 ml) and the volume of the mixture were finally adjusted to 3 ml with methanol, shaken vigorously and left standing at room temperature for 10 min. After the mixture had reached equilibrium, the absorbance of the solution was measured spectrophotometrically at 562 nm. All the experiments were carried out in triplicate, average and standard deviations was calculated. The percentage of inhibition of ferrozine –Fe²⁺ complex formation was calculated using the formula given below and reported in Table-2

\[
\% \text{Inhibition} = \frac{A_0 - (A_1 - A_2)}{A_0} \times 100
\]

Where A0 is the absorbance of the control containing iron (II) chloride and ferrozine only, A1 is the absorbance in the presence of the tested sample and A2 is the absorbance of the sample under identical conditions as A1 with water instead of iron (II) chloride solution.

<table>
<thead>
<tr>
<th>S. No.</th>
<th>Compound Name</th>
<th>% of inhibition</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>13a</td>
<td>64.0±0.15</td>
</tr>
<tr>
<td>2</td>
<td>13b</td>
<td>63.2±0.06</td>
</tr>
<tr>
<td>3</td>
<td>13c</td>
<td>59.7±0.38</td>
</tr>
<tr>
<td>4</td>
<td>13d</td>
<td>23.1±0.81</td>
</tr>
<tr>
<td>5</td>
<td>13e</td>
<td>17.3±0.61</td>
</tr>
<tr>
<td>6</td>
<td>13f</td>
<td>29.6±0.35</td>
</tr>
<tr>
<td>7</td>
<td>13g</td>
<td>30.3±0.82</td>
</tr>
<tr>
<td>8</td>
<td>13h</td>
<td>15.7±0.20</td>
</tr>
<tr>
<td>9</td>
<td>13i</td>
<td>22.5±0.50</td>
</tr>
<tr>
<td>10</td>
<td>13j</td>
<td>89.9±0.52</td>
</tr>
<tr>
<td>11</td>
<td>13k</td>
<td>19.3±0.35</td>
</tr>
<tr>
<td>12</td>
<td>13l</td>
<td>51.3±0.58</td>
</tr>
<tr>
<td>13</td>
<td>13m</td>
<td>43.9±0.95</td>
</tr>
<tr>
<td>14</td>
<td>13n</td>
<td>35.3±0.13</td>
</tr>
<tr>
<td>15</td>
<td>BHT</td>
<td>90.5±3.12</td>
</tr>
</tbody>
</table>

Table 1: Antioxidant activity of Schiff bases (13a-n)
Table 2: Metal chelating activity of Schiff bases (13a-n)

<table>
<thead>
<tr>
<th>S. No.</th>
<th>Compound name</th>
<th>% of inhibition</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>13a</td>
<td>87.33±2.52</td>
</tr>
<tr>
<td>2</td>
<td>13b</td>
<td>84.33±1.26</td>
</tr>
<tr>
<td>3</td>
<td>13c</td>
<td>69.33±0.58</td>
</tr>
<tr>
<td>4</td>
<td>13d</td>
<td>------</td>
</tr>
<tr>
<td>5</td>
<td>13e</td>
<td>34.60±1.35</td>
</tr>
<tr>
<td>6</td>
<td>13f</td>
<td>87.42±0.40</td>
</tr>
<tr>
<td>7</td>
<td>13g</td>
<td>24.67±1.53</td>
</tr>
<tr>
<td>8</td>
<td>13h</td>
<td>------</td>
</tr>
<tr>
<td>9</td>
<td>13i</td>
<td>5.37±0.15</td>
</tr>
<tr>
<td>10</td>
<td>13j</td>
<td>45.33±0.81</td>
</tr>
<tr>
<td>11</td>
<td>13k</td>
<td>15.17±0.32</td>
</tr>
<tr>
<td>12</td>
<td>13l</td>
<td>------</td>
</tr>
<tr>
<td>13</td>
<td>13m</td>
<td>------</td>
</tr>
<tr>
<td>14</td>
<td>13n</td>
<td>20.07±0.90</td>
</tr>
<tr>
<td>15</td>
<td>EDTA</td>
<td>87.3±0.26</td>
</tr>
</tbody>
</table>

Antimicrobial activity

The antibacterial activities of (13a-n) were determined by the well plate method using Mueller-Hinton Agar [43]. The in vitro antibacterial activity was carried out using 24 h old bacterial cultures. In this present work B. subtilis, E. coli and P. aeruginosa bacterial strain was used to investigate the activity. The test compounds (13a-n) and standard (Streptomycin) were dissolved in dimethyl sulfoxide (DMSO) at different concentrations. Twenty ml of sterilized agar media was poured into each pre-sterilized Petri dish. About 60 µl of bacterial culture suspension were poured and swabbed with the pre-sterilized cotton swabs. Six mm diameter well were then punched carefully using a sterile cork borer and 60 µl of test solution of different concentration were added into each labeled well. The plates were incubated for 24 h at 37 °C.

The inhibition zone around the well in each plate was measured in mm. experiments were in triplicates, average and standard deviations were calculated. The antimicrobial results were compared with Streptomycin as standard and summarized in table 3.

Table 3: Antimicrobial activity of Schiff bases (13a-n)

<table>
<thead>
<tr>
<th>Concentration in mg/ml</th>
<th>Escherichia coli</th>
<th>Bacillus subtilis</th>
<th>Pseudomonas aeruginosa</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>0.5</td>
<td>0.5</td>
<td>0.5</td>
</tr>
<tr>
<td>Streptomycin</td>
<td>19.6±0.32</td>
<td>17.57±0.60</td>
<td>22.43±0.40</td>
</tr>
<tr>
<td>Control</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>13a</td>
<td>13.37±0.32</td>
<td>9.43±0.40</td>
<td>10.73±0.64</td>
</tr>
<tr>
<td>13b</td>
<td>15.50±0.50</td>
<td>13.83±0.76</td>
<td>13.77±0.55</td>
</tr>
<tr>
<td>13c</td>
<td>12.53±0.32</td>
<td>9.33±0.58</td>
<td>11.2±0.35</td>
</tr>
<tr>
<td>13d</td>
<td>18.50±0.50</td>
<td>15.73±0.64</td>
<td>15.23±0.40</td>
</tr>
<tr>
<td>13e</td>
<td>17.0±0.75</td>
<td>15.67±0.58</td>
<td>15.27±0.46</td>
</tr>
<tr>
<td>13f</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>13g</td>
<td>15.17±0.15</td>
<td>12.17±0.29</td>
<td>15.43±0.75</td>
</tr>
<tr>
<td>13h</td>
<td>14.07±0.12</td>
<td>13.5±0.5</td>
<td>12.4±0.69</td>
</tr>
<tr>
<td>13i</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>13j</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>13k</td>
<td>18.4±0.36</td>
<td>16.03±0.47</td>
<td>17.63±0.71</td>
</tr>
<tr>
<td>13l</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>13m</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>13n</td>
<td>16.67±0.47</td>
<td>14.83±0.76</td>
<td>15.3±0.36</td>
</tr>
</tbody>
</table>

Note: NA-no activity

RESULTS AND DISCUSSION

Chemistry

The key starting material octahydro-1H-pyrrolo[3,4-b]pyridine (7) was prepared from the known literature method using the scheme-1.

In an effort to develop the synthesis of novel fused heterocyclic compound Schiff bases containing octahydro-1H-pyrrolo[3,4-b]pyridine ring, a synthetic approach was done and is depicted in Scheme 2 and Scheme-3.

Reacting quinolinic acid (1) with acetic anhydride followed by treatment with benzyl amine gives N-benzyl quinolinic acid imide (4), which on reduction with palladium carbon yields 8-benzyl-7,9-dione-2,8-diazabicyclo[4.3.0]nonane (5). Further on reduction with sodium bis(2-methoxyethoxy)aluminum-hydride (Vitride) to form 8-benzyl-2,8-diazabicyclo[4.3.0]nonane (6). This after resolution and followed by debenzylation gave octahydro-1H-pyrrolo[3,4-b]pyridine (7).

Scheme 1: Synthetic scheme for the preparation of octahydro-1H-pyrrolo[3,4-b]pyridine

Scheme 6: In vitro antimicrobial activity of Schiff bases (13a-n)
reported for the fluoro quinoline drugs like moxifloxacin and pradofloxacin and showed very good activity against gram positive respiratory infections (pneumonia, chronic sinusitis, and chronic spectrum antibacterial agent, employed for the treatment of and gram negative bacteria. Moxifloxacin is a synthetic broad well reported by several authors for their antimicrobial, antioxid ant activity against various microbes. In this research article, we reporting and their biological activities. The antimicrobial activity of the Various symmetrical and unsymmetrical bis Schiff bases have been.

**Antioxidant activity**

The antioxidant activity of novel Schiff bases (13a-n) was determined by DPPH scavenging activity method as described by Brand-Williams et al., with some modifications. This assay is based on the determination of the concentration of 2, 2-diphenyl-1-picyrylhydrazyl (DPPH) in methanolic solution, after adding the antioxidants. DPPH concentration is reduced by the existence of an antioxidant at 515 nm and the absorption gradually disappears with time. UV/VIS spectrophotometer was used to determine the antioxidant activity of each sample.

The antioxidant activities of newly synthesised compounds (13a-n) were determined by DPPH method and were compared with reference standard butylated hydroxyl toluene (BHT). The results show that the compound (13j) was acts as a good antioxidant. The compounds13j substituted with hydroxyl and methoxy functional group showed good antioxidant activity, while the other showed a week or no activity.

**Metal ion chelating assay**

The ability of samples to chelate iron (II) ion was estimated using the method reported by Dinis et al. The metal chelating activity of newly synthesised compounds (13a-n) was determined and compared with reference standard ethylenediaminetetraacetic acid (EDTA). Compounds like 13a, 13b, 13f showed good chelating activity. While the other showed less or no activity.

**Antimicrobial activity**

All the synthesized compounds (13a-n) were screened for their antibacterial activity against B. subtilis, E. coli and P. aeruginosa bacterial strain. Minimum inhibitory concentration (MIC) of all compounds was determined, which is defined as the lowest concentration of inhibitor at which bacterial growth was not visually apparent.

Investigation on antibacterial screening data (table 1) showed some of the compounds were active against three human pathogenic bacteria. The antibacterial activities of (13a-n) were determined by the well plate method using Mueller-Hinton Agar. The compound substituted with13d, 13e, 13k, and 13n showed good activity against E. Coli bacteria. The compounds substituted with 13d showed good activity against B. subtilis. Compounds substituted with 13d, 13e, and 13k showed excellent activity against P. Aeruginosa while the other showed no or moderate activity.

**CONCLUSION**

In this article, we report the synthesis of certain Schiff Bases of Octahydro-1H-pyrrolo[3,4-b]pyridine derivatives (13a-n), starting from commercially available quinolinic acid and characterized by spectral data. An investigation of their biological activity revealed that some compounds showed good antioxidant, chelating and antimicrobial properties. Compound 13j showed good antioxidant activity while compounds13a, 13b, and 13f showed good chelating agents, the compounds substituted with 13d showed good activity against B. subtilis. Compounds substituted with 13d, 13e, and 13k showed excellent activity against P. Aeruginosa while the other showed no or moderate activity.

**ACKNOWLEDGEMENT**

The author thankful to the chairman, Department of studies in Chemistry, Mysore University, Mysore, India for their help and support to the research.
CONFICT OF INTERESTS
Declared None

REFERENCES
43. Aparadh VT, Naik VV, Karadge BA. Anti-oxidative properties (TPC, DPPH, FRAP, Metal chelating ability, reducing power and TAC), with in some Cleome species. Ann Bot (Roma) 2012;2:49-56.